Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Sumanta K. Pal et al.|Journal of Clinical Oncology|2020Cited by 31
Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.Ziad Bakouny, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2020Cited by 20
The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).Andrew Schmidt, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2021Cited by 13
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.Shaan Dudani, Daniel Yick Chin Heng, Chun Loo Gan et al.|Journal of Clinical Oncology|2020Cited by 11
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Chun Loo Gan, Daniel Yick Chin Heng, Shaan Dudani et al.|Journal of Clinical Oncology|2021Cited by 11